Back to the Future: Setting up MSC Clinical Trials for Success
Wednesday, May 29, 2024 10:45 AM - 11:45 AM
Room 202-204
Roundtable
Organized by: ISCT MSC Committee
Moderator(s)
Assess ongoing MSC clinical trials to understand how clinical trial design, disease indication, MSC potency, dose, MSC fatigue and lack of enhancement impact outcomes
Key Learning Objectives
1. Understand latest updates on MSC clinical investigation in GvHD, Stroke, Heart Disease, Osteoarthritis
2. Discuss and debate differences in clinical trial design, control groups, and selection of patient endotypes in different clinical trials
3. Discuss MSC characterization of critical quality attributes or potency assays
Moderator(s)
- Dominique Farge, MD, PhD, St Louis Hospital Assistance Publique-Hôpitaux De Paris Paris-Cité University, France
- Sowmya Viswanathan, PhD, University Health Network, Canada
- Eleuterio Lombardo, PhD, Takeda, Spain
- Fermín Sánchez‐Guijo, MD, PhD, Univesity Hospital of Salamanca, University of Salamanca, Spain
- Kilian Kelly, PhD, Cynata, Australia
- Pawan Gupta, MD, DNB, PhD, MNAMS, Stempeutics Research Pvt. Ltd., India
Assess ongoing MSC clinical trials to understand how clinical trial design, disease indication, MSC potency, dose, MSC fatigue and lack of enhancement impact outcomes
Key Learning Objectives
1. Understand latest updates on MSC clinical investigation in GvHD, Stroke, Heart Disease, Osteoarthritis
2. Discuss and debate differences in clinical trial design, control groups, and selection of patient endotypes in different clinical trials
3. Discuss MSC characterization of critical quality attributes or potency assays
Fermin Sanchez-Guijo
Head Hematology Dpt & Full-Professor of Medicine
Hospital Universitario de Salamanca, Universidad de Salamanca
Panelist
Head Hematology Dpt & Full-Professor of Medicine
Hospital Universitario de Salamanca, Universidad de Salamanca
Panelist
